

***Fiscal Year 2022 Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Applied Research Award (ARA)</b> <b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-22-PRORP-ARA</p>	<p>Independent investigators at all academic levels (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports applied research applications focused on advancing optimal treatment and restoration of function for individuals with musculoskeletal injuries sustained during combat, combat-related activities, and non-battle injuries that impact unit readiness and the ability to return to duty/work.</li> <li>• Proposed research should be supported by preliminary and/or published data and have the potential to make significant advancements toward clinical translation.</li> <li>• <i>Clinical research and clinical trials are not allowed under this award mechanism.</i></li> <li>• <b>Applications must address one of the following FY22 PRORP ARA Focus Areas:</b> <ul style="list-style-type: none"> <li>○ <b>Limb Stabilization and Protection</b></li> <li>○ <b>Retention Strategies</b> <ul style="list-style-type: none"> <li>– Battlefield Care</li> <li>– Return to Duty</li> </ul> </li> <li>○ <b>Osseointegration</b></li> <li>○ <b>Composite Tissue Regeneration</b></li> </ul> </li> <li>• <i>Pre-application submission is required; application submission is by invitation only.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$725,000</b> for total costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 16, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 13, 2022 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Trial Award (CTA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-22-PRORP-CTA</p>	<p>Independent investigators at all academic levels (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return to duty/work rates.</li> <li>• <b>Funding must support a clinical trial and may not be used for animal or preclinical research studies.</b></li> <li>• Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration or relevant national regulatory agency <b>within 6 months of the award date.</b></li> <li>• <b>Applications must address one of the following FY22 PRORP CTA Focus Areas:</b> <ul style="list-style-type: none"> <li>○ <b>Limb Stabilization and Protection</b></li> <li>○ <b>Retention Strategies</b> <ul style="list-style-type: none"> <li>– Battlefield Care</li> <li>– Return to Duty</li> </ul> </li> <li>○ <b>Translation of Early Findings</b> <ul style="list-style-type: none"> <li>– Soft Tissue Trauma</li> <li>– Fracture-Related Infection</li> </ul> </li> </ul> </li> <li>• All applications, regardless of the selected Focus Area, are eligible for <b>Research Level 1.</b></li> <li>• Applications submitted to address the <i>Translation of Early Findings – Soft Tissue Trauma</i> Focus Area <u>and</u> include the Collaborative Care Option are eligible for <b>Research Level 2.</b></li> <li>• <b>Pre-application submission is required; application submission is by invitation only.</b></li> </ul>	<p><b>Research Level 1:</b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$2.5 million (M)</b> for total costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul> <p><b>Research Level 2:</b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$3.0M</b> for total costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 16, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 13, 2022 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Translational Research Award (CTRA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-22-PRORP-CTRA</p>	<p>Independent investigators at all academic levels (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial.</li> <li>• <b><i>Funding must support clinical research studies involving humans.</i></b></li> <li>• Preliminary data relevant to the proposed research project are required.</li> <li>• Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration or relevant national regulatory agency <b><i>within 12 months of the award date.</i></b></li> <li>• <b>Applications must address one of the following FY22 PRORP CTRA Focus Areas:</b> <ul style="list-style-type: none"> <li>○ <b>Retention Strategies</b> <ul style="list-style-type: none"> <li>– Battlefield Care</li> <li>– Return to Duty</li> </ul> </li> <li>○ <b>Tissue Regeneration Therapeutics</b></li> <li>○ <b>Compartment Syndrome and/or Reperfusion Injury</b></li> <li>○ <b>Osseointegration</b></li> <li>○ <b>Prostheses and Orthoses</b></li> </ul> </li> <li>• <b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$1.5M</b> for total costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 16, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 13, 2022 11:59 p.m. Eastern time</p>